937166-24-0 Usage
Uses
Used in Pharmaceutical Industry:
1-(2-BROMOALLYL)-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE is used as a chemical intermediate for the development of new pharmaceuticals. Its unique structure, which includes a bromoallyl group and a methylpyrimidine-2,4(1H,3H)-dione moiety, may provide valuable properties and reactivity for the creation of novel drug candidates.
Additionally, as its properties and reactivity are still under investigation, it may find applications in other areas of the pharmaceutical industry, such as drug delivery systems or as a component in the synthesis of other bioactive compounds. Further research is necessary to explore these potential uses and to optimize its application in the development of new medications.
Check Digit Verification of cas no
The CAS Registry Mumber 937166-24-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,7,1,6 and 6 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 937166-24:
(8*9)+(7*3)+(6*7)+(5*1)+(4*6)+(3*6)+(2*2)+(1*4)=190
190 % 10 = 0
So 937166-24-0 is a valid CAS Registry Number.
937166-24-0Relevant academic research and scientific papers
Piperno, Anna,Rescifina, Antonio,Corsaro, Antonino,Chiacchio, Maria A.,Procopio, Antonio,Romeo, Roberto
, p. 1517 - 1521 (2007)
The synthesis of hitherto unknown 1-[3-(hydroxymethyl)-2-methyl-4- methyleneisoxazolidin-5-yl]thymine (5), 1-{(Z)-[3-(hydroxymethyl)-2- methylisoxazolidin-4-ylidene]methyl}-thymine (6), and 1-{(E)-[3-(hydroxymethyl)- 2-methylisoxazohdin-5-ylidene]methyl}thymine (7) is described. The first compound can be regarded as a N,O-analogue of Entecavir and DMDC, which contains thymine as a nucleobase. The key allenic nucleobase was prepared in good yields starting from 2,3-dibromopropene. The subsequent 1,3-dipolar cyclo-addition proceeded with good site selectivity to give 5 and regioisomeric nucleosides 6 and 7. Wiley-VCH Verlag GmbH & Co. KGaA, 2007.
